High Protein Diet and Atherosclerosis

Atherosclerosis Clinical Trial

— HPA  

Official title:

Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05235464
• Other study ID #: 2097342
• Status: Recruiting
• Phase: N/A
• Start date: March 13, 2023
• Est. completion date: March 31, 2027

Study information

• Verified date: March 2024
• Source: University of Missouri-Columbia
• Contact: Bettina Mittendorfer, PhD
• Phone: 6186103465
• Email: b.mittendorfer[@]missouri.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas "lean" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: March 31, 2027
• Est. primary completion date: March 31, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• >=45 and <=75 years of age

• body mass index >=25.0 and <40.0 kg/m2

Exclusion Criteria:

• <45 and >75 years of age

• body mass index <25.0 or >39.9 kg/m2

• plasma triglyceride <125 mg/dl

• history of or current significant organ system dysfunction

• allergies or intolerances to meal ingredients

• use of medications or dietary supplements that could confound the study outcomes

• engaged in regular structured exercise >150 min per week

• alcohol use disorder

• premenopausal women

• persons who smoke

• prisoners

• inability to grant voluntary informed consent

Related Conditions & MeSH terms

• Atherosclerosis

Intervention

Other:
• Standard meal
Standard meal
• High animal protein meal
Meal with high animal protein content
• High plant protein meal
Meal with high plant protein content
• High plant protein meal with additional leucine
Meal with high plant protein content and additional leucine

Locations

Country	Name	City	State
United States	University of Missouri School of Medicine	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monocyte p-S6 content	phospho-S6 content in monocytes	change from at 1 hour before meal intake and 3 hours after the meal